BioCatalystWatch
DYNWorkspace / DYN / OverviewCompany library
Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. (DYN)

Website

Price
Market cap
Next catalystJan 21, 2027Zeleciment rostudirsen — exon 51 DMD; DELIVER and FORZETTO · Regulatory decisionSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Zeleciment basivarsen

mutant DMPK RNA × TfR1

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Zeleciment basivarsen

mutant DMPK RNA × TfR1

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

DYNE-253

PreINDP1P2P3FilingApproved
DYNE-302

DUX4 mRNA × TfR1

DYNE-245

PreINDP1P2P3FilingApproved
DYNE-244

PreINDP1P2P3FilingApproved
DYNE-255

PreINDP1P2P3FilingApproved
DYNE-401

TfR1

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

DYN PR & News

DYN SEC archive